1266 related articles for article (PubMed ID: 8595084)
1. General pharmacology of the new antimuscarinic compound vamicamide.
Yamamoto T; Honbo T; Tokoro K; Kojimoto Y; Kodama R; Ohtsuka M; Shimomura K
Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
[TBL] [Abstract][Full Text] [Related]
2. General pharmacology of recombinant human basic fibroblast growth factor.
Okumura M; Yajima M; Nishimura T; Ikeda H; Nishimori T
Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
[TBL] [Abstract][Full Text] [Related]
3. Urinary bladder-selective action of the new antimuscarinic compound vamicamide.
Oyasu H; Yamamoto T; Sato N; Sawada T; Ozaki R; Mukai T; Ozaki T; Nishii M; Sato H; Fujiwara T
Arzneimittelforschung; 1994 Nov; 44(11):1242-9. PubMed ID: 7848339
[TBL] [Abstract][Full Text] [Related]
4. General pharmacological properties of the new vasodilator flosequinan.
Ikezono K; Fujita S; Umezato M; Hosoki E; Toba Y; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
[TBL] [Abstract][Full Text] [Related]
5. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
Saito T; Ukai K; Masuda T; Nakagawa T; Kimura K; Fujii M; Wakatsuki K; Saeki M; Kasai H
Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
Kitano Y; Makino M; Usui C; Takasuna K; Kasai Y; Hirohashi M; Tamura K; Takayama S; Kojima H; Iizuka H
Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
[TBL] [Abstract][Full Text] [Related]
7. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
Andoh K; Kimura T; Saeki I; Tabata R; Yamazaki S; Eguchi I; Hanazuka M; Horii D; Munt PL; Davis AS
Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological properties of the main metabolite of flosequinan.
Fujita S; Ikezono K; Umezato M; Hosoki E; Toba Y; Ishikawa M; Kusunoki A; Shintani S
Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
[TBL] [Abstract][Full Text] [Related]
9. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol.
Terai T; Kusunoki T; Kita Y; Yoshida K; Akahane A; Shiokawa Y; Kohno Y; Horiai H; Mori J; Mine Y; Kohsaka M
Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological studies on timiperone, a new neuroleptic drug Part II: General pharmacological properties.
Yamasaki T; Kojima H; Tanaka M; Aibara S; Hirohashi M; Kasai Y; Tsubokawa M; Watanabe K; Akashi A
Arzneimittelforschung; 1981; 31(4):707-15. PubMed ID: 6113834
[TBL] [Abstract][Full Text] [Related]
11. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
Murata T; Murai T; Kanai T; Ogaki Y; Sanai K; Kanda H; Sato S; Kajikawa N; Umetsu T; Matsuura H
Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
[TBL] [Abstract][Full Text] [Related]
12. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics.
Yamamoto S; Takemori E; Hasegawa Y; Kuroda K; Nakao K; Inukai T; Sakonjyo H; Nishimura T; Nishimori T
Arzneimittelforschung; 1991 Sep; 41(9):913-23. PubMed ID: 1796919
[TBL] [Abstract][Full Text] [Related]
13. General pharmacology of the new quinolone antibacterial agent levofloxacin.
Takasuna K; Kasai Y; Usui C; Takahashi M; Hirohashi M; Tamura K; Takayama S
Arzneimittelforschung; 1992 Mar; 43(3A):408-18. PubMed ID: 1622443
[TBL] [Abstract][Full Text] [Related]
14. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
Matsuno Y; Taira N; Fujitani B; Ito T; Kadokawa T
Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
[TBL] [Abstract][Full Text] [Related]
15. General pharmacology of the novel antiepileptic compound zonisamide. 2nd communication: effects on cardiovascular, visceral, renal and blood functions.
Nakatsuji K; Matsuno Y; Nakamura N; Fujitani B; Ito T; Kadokawa T
Arzneimittelforschung; 1987 Oct; 37(10):1131-6. PubMed ID: 3435584
[TBL] [Abstract][Full Text] [Related]
16. General pharmacological profile of the new anti-ulcer drug 3-[[[2-(3,4-dimethoxyphenyl)ethyl]carbamoyl]methyl]-amino-N -methylbenzamide.
Hirohashi M; Takasuna K; Kasai Y; Usui C; Tamura K; Kojima H
Arzneimittelforschung; 1993 May; 43(5):569-77. PubMed ID: 8329002
[TBL] [Abstract][Full Text] [Related]
17. General pharmacological profiles of the new beta-adrenoceptor antagonist carvedilol.
Hirohashi M; Takasuna K; Tamura K; Yamaguchi K; Maekawa K; Yamada S; Iwasaki S; Yoshida M; Nomura M; Taguchi K
Arzneimittelforschung; 1990 Jul; 40(7):735-46. PubMed ID: 1977393
[TBL] [Abstract][Full Text] [Related]
18. [General pharmacology of T-3761, a new oral quinolone antibacterial agent (2). Effect on the respiratory and cardiovascular systems, autonomic nervous system and other functions].
Furuhata K; Hiraiwa T; Terashima N; Arai H; Ono S; Hashiba K; Maekawa M; Kitamura K; Nakada Y; Mori Y
Jpn J Antibiot; 1995 May; 48(5):706-32. PubMed ID: 7637205
[TBL] [Abstract][Full Text] [Related]
19. General pharmacology of loracarbef in animals.
Shetler T; Bendele A; Buening M; Clemens J; Colbert W; Deldar A; Helton D; McGrath J; Shannon H; Turk J
Arzneimittelforschung; 1993 Jan; 43(1):60-70. PubMed ID: 8447851
[TBL] [Abstract][Full Text] [Related]
20. General pharmacology of the new antiviral agent SK 1899.
Ryu KH; Rhee HI; Jung I; Kim TS; Lee SJ; Im GJ; Lee N; Ryu DH; Kim YW; Kim JJ; Chang K; Lee BH; Shin HS; Kim EJ; Kim KH; Kim DK
Arzneimittelforschung; 2000 Apr; 50(4):395-403. PubMed ID: 10800640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
